NCT03974217 2026-02-25Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer InstitutePhase 1 Active not recruiting13 enrolled
NCT04874480 2026-01-09Tegavivint for the Treatment of Relapsed or Refractory LeukemiaM.D. Anderson Cancer CenterPhase 1 Active not recruiting9 enrolled